BlackRock Fund Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

BlackRock Fund Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$21.5M	Buy	3,401,744 +374,149	+12%	+$1.95M	﹤0.01%	2142
2016 Q3	$13.4M	Buy	3,027,595 +177,357	+6%	+$708K	﹤0.01%	2299
2016 Q2	$8.1M	Buy	2,850,238 +49,452	+2%	+$154K	﹤0.01%	2523
2016 Q1	$7.93M	Buy	2,800,786 +11,202	+0.4%	+$49.6K	﹤0.01%	2488
2015 Q4	$28.8M	Sell	2,789,584 -122,144	-4%	-$1.21M	0.01%	1822
2015 Q3	$33.2M	Buy	2,911,728 +88,010	+3%	+$1.17M	0.01%	1685
2015 Q2	$42.2M	Sell	2,823,718 -37,182	-1%	-$423K	0.01%	1635
2015 Q1	$25.8M	Buy	2,860,900 +56,359	+2%	+$584K	0.01%	1934
2014 Q4	$34.1M	Buy	2,804,541 +256,371	+10%	+$2.83M	0.01%	1732
2014 Q3	$24.9M	Sell	2,548,170 -9,942	-0.4%	-$122K	0.01%	1815
2014 Q2	$32.6M	Buy	2,558,112 +1,659,980	+185%	+$16.2M	0.01%	1694
2014 Q1	$9.5M	Buy	898,132 +63,343	+8%	+$675K	﹤0.01%	2433
2013 Q4	$6.34M	Buy	834,789 +686,454	+463%	+$4.35M	﹤0.01%	2662
2013 Q3	$1.08M	Buy	148,335 +24,350	+20%	+$124K	﹤0.01%	3177
2013 Q2	$192K	Buy	+123,985	New	+$214K	﹤0.01%	3331

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock Fund Advisors's BCRX Position: Q4 2016 in Review

BlackRock Fund Advisors increased its BioCryst Pharmaceuticals (BCRX) stake by 12% in Q4 2016, buying an estimated $1.95M and bringing the position to 3,401,744 shares worth $21.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2142.

BlackRock Fund Advisors first reported a position in BCRX in Q2 2013 and has held it in 15 quarters since. The position peaked at $42.2M in Q2 2015. 112 funds tracked by Wall St. Rank hold BCRX as of Q4 2016.

BlackRock Fund Advisors held 3,401,744 shares of BioCryst Pharmaceuticals worth $21.5M as of Q4 2016.
BlackRock Fund Advisors bought 374,149 BioCryst Pharmaceuticals shares in Q4 2016, an estimated $1.95M.
BioCryst Pharmaceuticals made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #2142 holding.
BlackRock Fund Advisors first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
BlackRock Fund Advisors's BioCryst Pharmaceuticals position peaked at $42.2M in Q2 2015.
112 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.